Breast Recurrence Score Test Market Size & Share, by Type (Oncotype, MammaPrint), End User (Hospitals, Diagnostic Laboratories, Research Institutions) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5394
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Breast Recurrence Score Test Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of breast recurrence score test was over USD 10 Billion. The increasing emphasis on value-based healthcare is one of the main growth drivers fueling the market. The shift towards value-based healthcare is transforming the landscape of medical practices, emphasizing the importance of outcomes that matter most to patients. In the context of breast cancer, where treatment decisions have profound implications for patients' quality of life, value-based healthcare encourages the adoption of diagnostic tools that not only improve clinical outcomes but also contribute to cost-effectiveness and resource optimization. A study published demonstrated that the use of the Oncotype DX Breast Recurrence Score Test led to a significant reduction in chemotherapy use among patients with early-stage, estrogen receptor-positive breast cancer. The study reported a 46.6% reduction in the use of chemotherapy.

The breast recurrence score test is a diagnostic tool used in the field of breast cancer management to assess the risk of recurrence in early-stage, hormone receptor-positive breast cancer patients. This test provides valuable information to help guide treatment decisions, particularly with regard to whether or not to administer chemotherapy in addition to hormonal therapy. The market for breast recurrence score testing includes competition from other genetic tests and platforms aimed at assessing breast cancer prognosis and treatment planning.


Breast Recurrence Score Test Market
Get more information on this report: Request Free Sample PDF


Breast Recurrence Score Test Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~8%

Base Year Market Size (2023)

~ USD 10 Billion

Forecast Year Market Size (2036)

~ USD 20 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Breast Recurrence Score Test Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Increasing Incidence of Breast Cancer: Breast cancer is one of the most common cancer types worldwide, and its incidence has been steadily rising. According to the World Cancer Research Fund, breast cancer accounted for nearly 12% of new cancer cases in 2020, making it the most common cancer among women globally. As the incidence of breast cancer continues to grow, the demand for accurate diagnostic tools such as the Breast Recurrence Score Test increases. The test helps in stratifying patients into different risk categories, enabling personalized treatment decisions, which can lead to more efficient healthcare resource utilization and better outcomes for patients.
  • Expanding Awareness and Education: The breast cancer community has been actively promoting awareness and education. Organizations like Susan G. Komen have played a crucial role in educating both patients and healthcare providers about the importance of early detection and the significance of diagnostic tests like the Breast Recurrence Score Test. Increased awareness has led to more patients and healthcare professionals seeking out and prescribing these tests.
  • Patient-Centered Care: Modern healthcare is increasingly focused on patient-centered care. Patients are becoming more engaged in their treatment decisions and are seeking options that offer the best outcomes with minimal side effects. The Breast Recurrence Score Test aligns perfectly with this trend by providing patients with information that empowers them to make informed choices about their treatment.

Challenges

  • Cost and Accessibility: One of the primary challenges is the cost of the test and its accessibility. While insurance coverage has expanded in recent years, not all patients have access to the test, and the out-of-pocket costs can be prohibitive for some. This can lead to disparities in care, where some patients may not benefit from the test due to financial constraints. While insurance coverage for the test has improved over the years, there can still be significant variability in the extent of coverage. Some insurance policies may cover the entire cost of the test, while others may cover only a portion of it. This variability can lead to inconsistencies in patient access to the test, depending on their insurance provider and policy type.
  • Variability in Insurance Coverage
  • Awareness and Knowledge among Healthcare Personnel


Breast Recurrence Score Test Segmentation

Type (Oncotype, MammaPrint)

The MammaPrint segment in the breast recurrence score test market is estimated to gain the largest revenue share of 60% in the year 2036. The competitive landscape in the breast cancer diagnostic market encourages innovation and expansion. Diagnostic companies and healthcare institutions actively collaborate to ensure broader access to MammaPrint and similar tests. The market for breast cancer diagnostics is competitive, with multiple tests and providers seeking to offer their services. Competition drives innovation, leading to the development of more advanced and cost-effective tests. MammaPrint segment of the market is driven by several factors, including the increasing incidence of breast cancer, advancements in personalized medicine, regulatory support, clinical validation and research, patient-centered care, expanding clinical evidence and adoption, and a competitive landscape.

End User (Hospitals, Diagnostic Laboratories, Research Institutions)

The hospitals segment in the breast recurrence score test market is expected to garner a significant share in the year 2036. The rising incidence of breast cancer is a significant growth driver for the Hospitals segment of the market. As breast cancer becomes more prevalent, hospitals are at the forefront of diagnosing and treating patients. According to the American Cancer Society, in the United States, there were an estimated 281,550 new cases of invasive breast cancer among women in 2021. Breast cancer is the most commonly diagnosed cancer in women, with one in eight women in the United States being diagnosed in their lifetime. The increasing incidence of breast cancer means that hospitals are seeing a growing number of breast cancer patients. This drives the demand for diagnostic tests like the Breast Recurrence Score Test, which provide critical information for treatment decisions.

Our in-depth analysis of the global breast recurrence score test market includes the following segments:

                            Type

  • Oncotype
  • MammaPrint

                            End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Breast Recurrence Score Test Industry - Regional Synopsis

APAC Market Forecast

The breast recurrence score test market in the Asia Pacific region is projected to hold the largest market share of 38% by the end of 2036. The Asia Pacific region, like many other parts of the world, is shifting towards patient-centered care, emphasizing shared decision-making and patient empowerment. The Breast Recurrence Score Test aligns with this trend by providing patients with information to actively participate in their treatment decisions. It empowers patients and their healthcare providers to make informed choices about their treatment plans, enhancing patient satisfaction and demand for tests that enable them to be active participants in their healthcare. Asia Pacific region is experiencing significant growth in the market due to factors such as the increasing incidence of breast cancer, adoption of precision medicine, regulatory support, clinical validation and research, expanding clinical evidence and adoption, and the shift towards patient-centered care.

North American Market Statistics

The breast recurrence score test market in the North America region is projected to hold the second largest share during the forecast period. The rising incidence of breast cancer is a substantial growth driver for the market in North America. Breast cancer is the most common cancer among women in the United States, and its incidence continues to increase. In the United States, it is estimated that over 281,000 new cases of invasive breast cancer were diagnosed among women in 2021. The increasing incidence of breast cancer directly drives the demand for advanced diagnostic tools like the Breast Recurrence Score Test. As more women are diagnosed with breast cancer, there is a growing need for reliable tests to guide treatment decisions.

Research Nester
Breast Recurrence Score Test Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Breast Recurrence Score Test Landscape

top-features-companies
    • Genomic Health, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Agendia, Inc.
    • NanoString Technologies, Inc.
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific, Inc.
    • Illumina, Inc.
    • Roche Holdings AG
    • Biotheranostics, Inc.
    • Qiagen N.V.
    • Veracyte, Inc.

In-the-news

In The News

  • Agendia acquired Biomedex, a privately held molecular diagnostics company developing novel multi-cancer detection assays using liquid biopsy technology. This acquisition is expected to expand Agendia's portfolio of cancer diagnostic tests and increase its presence in the liquid biopsy market.
  • Agendia received FDA approval for its ColonPrint blood test, a liquid biopsy assay that is used to detect early-stage colon cancer. This approval marks a significant milestone for Agendia as it expands its product portfolio and offers a minimally invasive option for colon cancer screening.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5394
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of breast recurrence score test is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Genomic Health, Inc., Agendia, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Breast Recurrence Score Test Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying